重组人血管内皮抑制素联合TP方案治疗晚期非小细胞肺癌的临床观察  

Recombinant Human Endostatin Combined with Taxol Plus Cisplatin Regimen in Treatment of Advanced Non-small Cell Lung Cancer:Clinical Observation

作　　者：刘静[1] 王萍[1] 罗红兰[1] 王昌峰 陈传喜[1] 孙元利[1] 杨林[1] 仉丽[1] 焦克文[1] 桂瑞丰 陶朝慧 杨丽 

机构地区：[1]湖北省黄冈市中心医院,湖北黄冈438000 [2]湖北省黄冈市黄州区人民医院,湖北黄冈438000 [3]湖北省黄冈市中医院,湖北黄冈438000

出　　处：《中国现代医生》2010年第13期33-35,共3页China Modern Doctor

摘　　要：目的观察YH-16联合紫杉醇和顺铂(TP)治疗晚期非小细胞肺癌(NSCLC)的近期疗效和安全性,同时探讨循环血管内皮细胞(CECs)与该方案疗效的相关性。方法比较观察组和对照组治疗晚期NSCLC的近期疗效及毒副反应,采用流式细胞学法检测治疗前后外周血CECs数量。结果观察组和对照组有效率(CR+PR)分别为62.50%和22.22%(P=0.035);临床受益率分别为87.50%和50.00%(P=0.030);两组Ⅲ～Ⅳ级白细胞减少发生率分别为31.25%和33.33%;Ⅲ～Ⅳ级血小板减少发生率分别为25.00%和27.78%;恶心、呕吐发生率分别为56.24%和50.00%,差异无统计学意义(P>0.05)。结论 YH-16联合TP疗效优于单独应用TP,不增加毒副反应,CECs可能是一个较好的预测化疗联合抗血管生成治疗疗效的标志。Objective To investigate the short-term curative effect and safety of YH-16 in combination with Taxol plus cisplatin（TP）regimen in the treatment of advanced non-small cell lung caneer（NSCLC ）. Methods The recent efficacy and toxicity in the treatment of advanced NSCLC were compared between the experimental group and control group and the number of peripheral blood CECs before and after treatment was detected by flow cytometry. Results The effective rates（CR＋PR） of the experimental group and control group were 62.50% and 22.22% （P=0.035）, and the clinical benefit response（CBR） of two groups was 87.5% and 50%, respectively（P=0.030）. There was no significant difference in Ⅲ～Ⅳ grade neutropenia incidence rate, Ⅲ～Ⅳ grade thrombocytopenia and nausea and vomiting incidence rate between two groups. Conclusion YH-16 combined with TP regimen is better than TP regimen alone in the treatment of NSCLC,and there is no significant difference in side-effects between the YH-16 combined with TP regimen and the TP regimen alone. CECs could be a good marker to predict the efficacy of anti-angiogenesis therapy combined with chemotherapy.

关 键 词：非小细胞肺癌 重组人血管内皮抑制剂 联合化疗 血管/细胞学 

分 类 号：R734.2[医药卫生—肿瘤]